<DOC>
	<DOCNO>NCT01109043</DOCNO>
	<brief_summary>The b.p.m study perform gain insight course illness therapy subject , suffer hypertension elevate heart rate . This study show therapy bisoprolol ( Concor/Concor PLUS ) blood pressure lower ( antihypertensive ) drug lower blood pressure ( BP ) heart rate increase quality subject ' life .</brief_summary>
	<brief_title>Bisoprolol Hypertension : Effect Concomitant Elevated Heart Rate</brief_title>
	<detailed_description>The b.p.m study measure heart rate development whilst treat subject hypertension Concor [ bisoprolol ] Concor Plus [ bisoprolol + hydrochlorothiazide ( HCTZ ) ] . The objective study : After 6 month therapy treatment , 60 % subject show heart rate ≥ 80 beats/min . An improved quality life information 6 month therapy treatment , collect ask standardise question A decrease systolic diastolic BP 6 month present significant difference Digital sphygmomanometer ( BP measure device ) supply order document value BP heart rate . Blood pressure heart rate measure least 2 time , ideally 4 time per day . Furthermore , every subject additionally receive documentation sheet , he/she record measurement data . The documentation sheet part improvement quality life ; remove pass . Every subject explain use handle BP measuring device importance documentation . The assessment quality life must make begin end 6 month therapy . Within framework examination attend physician ask 8 standard question ( SQ-8 Short Form Health Survey ) . The questionnaire part quality life assessment . The main focus observation age group &lt; 55 year concomitant disease , diabetes ketohexokinase ( KHK ) .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Bisoprolol</mesh_term>
	<criteria>Subjects high blood pressure ( BP ) tachycardia Subjects essential hypotonia , angina pectoris Subjects essential hypertonia , therapy ßblockers diuretic sufficiently effective Precautions take case severe peripheral circulation disorder , diabetes ( especially time , blood sugar elevate ) , strict fast , case metabolic acidosis , atrioventricular block ( AV ) block grade I , Prinzmetal angina , additional therapy angiotensinconverting enzyme inhibitor ( ACEinhibitors ) , severe coronary cerebral sclerosis , hyperuricemia gout subject history severe hypersensitive reaction desensitization therapy ( excessive anaphylactic reaction , attenuate adrenergic counterregulation ) Special precaution must take subject family history suffer psoriasis , desensitization therapy ( also anamnestic subject ) , obstructive pulmonary disease account possibility initiation intensification bronchoconstriction , although , due mark ß1selectivity bisoprolol , risk lower nonselective ßreceptor blocker . The subject family history suffer psoriasis take Concor Plus careful assessment risk benefit ratio . The subject pheochromocytoma take Concor Plus , well ßblockers inhibit alphareceptors Subjects acute cardiac insufficiency , sinus sick syndrome , bradycardia anaemia Contraindicated medical condition bisoprolol define Product Information , i.e . know hypersensitivity active agent bisoprolol one inactive ingredient medication ; acute heart failure decompensation heart insufficiency , require therapy inotropic agent ; cardiogenic shock ; AV block grade II III ( absence cardiac pacemaker ) ; sick sinus syndrome , sinoatrial heart block ; symptomatic bradycardia ; symptomatic hypotonia ; severe asthma bronchiolus severe chronic obstructive airway disease ; advanced stage peripheral arterial disease Raynaud 's Syndrome ; untreated pheochromocytoma , metabolic acidosis Contraindicated medical condition bisoprolol + hydrochlorothiazide ( HCTZ ) define Product Information , i.e . hypersensitivity ingredient medication contain bisoprolol + HCTZ , uncompensated heart insufficiency , pulmonary hypertension , cardiogenic shock , AV block , grade II III . sick sinus syndrome ( absence cardiac pacemaker ) , sinoatrial heart block , severe bradycardia le 50 beats/min start treatment , hypotension ( systolic less 90 mmHg ) , acute asthmatic attack , intravenous administration calcium antagonists Verapamil type , simultaneous treatment monoamine oxidase inhibitor ( MAOinhibitors ) , advance stage peripheral circulation disorder , severe therapyresistant potassium deficiency , severe hyponatraemia , hypercalcaemia , severe renal dysfunction ( serum creatinin 1.8 mg/100 ml and/or creatinin clearance 30 ml/min ) ; acute glomerulonephritis ; liver coma ; child , previously treat ; pregnancy breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>54 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Bisoprolol</keyword>
	<keyword>Antihypertensive drug</keyword>
	<keyword>Blood pressure</keyword>
	<keyword>Quality life</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Ketohexokinase</keyword>
</DOC>